SAT0116 Safety and Efficacy of Ara290, a Non-Hematopoietic Erythropoietin Derived Peptide, in a 4 Weeks Phase II Open Label Trial in Patients with Active Rheumatoid Arthritis.
Authors: M. Van Den Broek, C. F. Allaart, M. Brines, A. Cerami, T. W. Huizinga
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Erythropoietin, a well-known stimulator of erythrocyte production, also has nonhematopoietic activities, that can generally be summarized as counteracting the actions of proinflammatory cytokines. It has been suggested previously that erythropoietin reduces disease activity in RA,<sup>12</sup> but given the side effects of administering high doses of erythropoietin, this treatment option has not been further investigated. <h3>Objectives</h3> To assess the safety and efficacy of ARA290, a non-hematopoietic erythropoietin derived peptide, in active rheumatoid arthritis patients in an open-label trial. <h3>Methods</h3> Fifteen patients were randomized to 4 weeks of intravenous treatment with 2mg of ARA290 either once or 3x/week. The latter was the highest dosing scheme tested in healthy volunteers. Safety was assessed weekly by history taking and laboratory tests. Disease activity, using the disease activity score (DAS), functional ability, using the Health Assessment Questionnaire (HAQ), and pain on a visual analogue scale (VAS pain) were measured weekly. Paired t tests or Wilcoxon matched-pair signed-rank tests were performed where appropriate to examine the difference between baseline and after treatment. <h3>Results</h3> Patient groups were similar in demographics and baseline disease characteristics: median disease duration was 8 years, in 93% rheumatoid factor and in 87% anti-citrullinated protein antibodies were present, 86% had erosive disease and half of the patients had failed on ≥1 biological. Three patients experienced a non-serious infection, leading to study withdrawal in one patient. One patient (treated 3x/week) was hospitalized in week 4 for observation of subjective paraesthesias where no abnormalities were found. One patient, who was treated 3x/week, had a good EULAR response, one (treated 1x/week) had a moderate response, two (one from each group) achieved low disease activity without a DAS decrease &gt;0.6 points and one (treated 3x/week) had a decrease &gt;0.6 points but still a DAS &gt;3.7. There was a (numerical) decrease in median VAS pain of 27 mm in the group treated 1x/week, p=0.03, and of 29 mm in the group treated 3x/week, p=0.2, and a decrease in median VAS global of 29 mm in the group treated 3x/week, p=0.03. No relevant changes in ESR and CRP or tender and swollen joint counts were observed. <h3>Conclusions</h3> This small open-label trial showed no major safety issues and possible (subjective and/or analgesic) efficacy of ARA290 in patients with active rheumatoid arthritis. <h3>References</h3> Kaltwasser JP, et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001;28:2430-6. Peeters HR, et al. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996;55:739-44. <h3>Disclosure of Interest</h3> M. Van Den Broek: None Declared, C. Allaart: None Declared, M. Brines Shareholder of: Araim pharmaceuticals, ARA290 was provided by Araim pharmaceuticals, A. Cerami Shareholder of: Araim pharmaceuticals, ARA290 was provided by Araim pharmaceuticals, T. Huizinga: None Declared